Last reviewed · How we verify
GC3107
GC3107 is a recombinant human albumin-fused interferon alpha (IFN-α) fusion protein that enhances antiviral and immunomodulatory activity.
GC3107 is a recombinant human albumin-fused interferon alpha (IFN-α) fusion protein that enhances antiviral and immunomodulatory activity. Used for Chronic hepatitis B, Chronic hepatitis C.
At a glance
| Generic name | GC3107 |
|---|---|
| Sponsor | Green Cross Corporation |
| Drug class | Interferon alpha fusion protein |
| Target | Type I interferon receptor (IFNAR) |
| Modality | Biologic |
| Therapeutic area | Virology / Immunology |
| Phase | Phase 3 |
Mechanism of action
GC3107 combines human serum albumin with interferon alpha to extend half-life and improve pharmacokinetics compared to native IFN-α. The albumin fusion allows for less frequent dosing while maintaining therapeutic interferon signaling through type I interferon receptors on immune and viral-infected cells.
Approved indications
- Chronic hepatitis B
- Chronic hepatitis C
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Hematologic abnormalities (thrombocytopenia, leukopenia)
- Elevated liver enzymes
- Depression / psychiatric effects
Key clinical trials
- A Study of GC3107(BCG Vaccine) in Healthy Infants (PHASE3)
- Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |